<?xml version="1.0" encoding="UTF-8"?>
<p id="p0210">Further bottlenecks are encountered during animal 
 <italic>in vivo</italic> studies; characterising immunogenicity and reactogenecity in relevant animal models is imperative for taking forward vaccine candidates into Phase 1. With this model there are further potential bottlenecks associated with Home Office approvals, and Containment Level 3 and 4 facilities depending on the pathogen of study, and supply of animals.
</p>
